NEW YORK, NY / ACCESSWIRE / February 14, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
TLS Shareholders Click Here: https://www.zlk.com/pslra-1/telos-corporation-loss-submission-form?prid=23641&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23641&wire=1
ASTR Shareholders Click Here: https://www.zlk.com/pslra-1/astra-space-inc-f-k-a-holicity-inc-loss-submission-form?prid=23641&wire=1
* ADDITIONAL INFORMATION BELOW *
Telos Corporation (NASDAQ:TLS)
TLS Lawsuit on behalf of: investors who purchased November 19, 2020 – November 12, 2021
Lead Plaintiff Deadline : April 8, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/telos-corporation-loss-submission-form?prid=23641&wire=1
According to the filed complaint, during the class period, Telos Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Transportation Security Administration (“TSA”) and Centers for Medicare and Medicaid Services (“CMS”) contracts, which constituted a majority of the Company’s future revenues, were not on track to commence as represented at the end of 2021 and in 2022; (2) Defendants lacked a reasonable basis and sufficient visibility to provide and affirm the Company’s 2021 guidance in the face of the uncertainty surrounding the TSA and CMS contracts; (3) COVID-19- and hacking scandal-related headwinds were throwing off the timing for performance of the TSA and CMS contracts and their associated revenues; (4) as a result, the guidance provided by Defendants was not in fact “conservative”; (5) as a result of the delays, Telos would be forced to dramatically reduce its revenue estimates; and (6) as a result of the foregoing, Defendants’ statements about Telos’ business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
FENC Lawsuit on behalf of: investors who purchased May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23641&wire=1
According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Astra Space Inc. f/k/a Holicity Inc. (NASDAQ:ASTR)
ASTR Lawsuit on behalf of: investors who purchased February 2, 2021 – December 29, 2021
Lead Plaintiff Deadline : April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/astra-space-inc-f-k-a-holicity-inc-loss-submission-form?prid=23641&wire=1
According to the filed complaint, during the class period, Astra Space Inc. f/k/a Holicity Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Astra cannot launch “anywhere”; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/688568/CLASS-ACTION-UPDATE-for-TLS-FENC-and-ASTR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders